Radiochemotherapy in brain-tumor patients was shown to cause gray matter (GM) volume and cerebral blood flow (CBF) changes. The interaction of these two effects, however, remains unclear. Here, we investigated GM volume and ASL CBF changes and their interaction in the healthy hemisphere of 38 glioblastoma patients undergoing radiochemotherapy with Temozolomide. We found a statistically significant CBF decrease with dependence on the RT-dose. PV-corrected results indicated that, while to a certain extent the apparent CBF decrease measured by ASL is caused by GM atrophy, there still remain significant CBF changes that cannot be explained by structural changes alone.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords